Ackerman Capital Advisors LLC Buys New Shares in Eli Lilly and Company (NYSE:LLY)

Ackerman Capital Advisors LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 257 shares of the company’s stock, valued at approximately $233,000.

Other hedge funds have also modified their holdings of the company. Tidemark LLC purchased a new position in Eli Lilly and Company during the 4th quarter worth approximately $29,000. Core Wealth Advisors Inc. lifted its position in Eli Lilly and Company by 188.2% during the fourth quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after purchasing an additional 32 shares during the period. Lynx Investment Advisory purchased a new stake in Eli Lilly and Company in the second quarter valued at $32,000. Frank Rimerman Advisors LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $37,000. Finally, St. Johns Investment Management Company LLC grew its holdings in Eli Lilly and Company by 123.3% during the fourth quarter. St. Johns Investment Management Company LLC now owns 67 shares of the company’s stock worth $39,000 after acquiring an additional 37 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the sale, the chief accounting officer now directly owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 22,206 shares of the company’s stock in a transaction on Friday, May 31st. The stock was sold at an average price of $822.11, for a total value of $18,255,774.66. Following the transaction, the insider now owns 98,401,604 shares in the company, valued at $80,896,942,664.44. The disclosure for this sale can be found here. Insiders sold 1,122,141 shares of company stock worth $991,938,411 in the last 90 days. Insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of analyst reports. BMO Capital Markets boosted their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. JPMorgan Chase & Co. increased their price target on shares of Eli Lilly and Company from $900.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Thursday, July 11th. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Guggenheim raised their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Finally, Truist Financial reiterated a “buy” rating and set a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Two equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus price target of $956.88.

Eli Lilly and Company Trading Down 0.2 %

Shares of NYSE LLY traded down $2.21 during trading on Monday, hitting $950.53. 2,162,276 shares of the company were exchanged, compared to its average volume of 3,090,682. The company has a debt-to-equity ratio of 1.90, a quick ratio of 1.03 and a current ratio of 1.35. Eli Lilly and Company has a 12-month low of $516.57 and a 12-month high of $972.53. The company has a fifty day moving average price of $886.32 and a 200-day moving average price of $815.20. The firm has a market capitalization of $903.39 billion, a PE ratio of 140.32, a P/E/G ratio of 1.81 and a beta of 0.41.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.55%. Eli Lilly and Company’s dividend payout ratio (DPR) is 76.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.